This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
by Zacks Equity Research
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
Zacks.com featured highlights include: AMN Healthcare Services, American Axle & Manufacturing, Generac, Silicon Motion Technology and Target
by Zacks Equity Research
Zacks.com featured highlights include: AMN Healthcare Services, American Axle & Manufacturing, Generac, Silicon Motion Technology and Target
5 Stocks Trading Near 52-Week High That Can Jump Further
by Aniruddha Ganguly
Investors target stocks that have been on a bullish run lately. Stocks like AMN, AXL, GNRC, SIMO and TGT that are seeing price strength have a high chance of carrying the momentum forward.
New Strong Buy Stocks for June 17th
by Zacks Equity Research
MT, FCF, SNA, DAR, and AMN have been added to the Zacks Rank #1 (Strong Buy) List on June 17, 2021.
AMN Healthcare (AMN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AMN Healthcare (AMN) is optimistic about maintaining its strength in staffing service as well as offering a broad array of services.
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
by Zacks Equity Research
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
Reasons to Add HealthEquity Stock (HQY) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity (HQY) on its slew of buyouts and strength in HSA.
Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia
by Zacks Equity Research
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.
Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT
by Zacks Equity Research
Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.
New Strong Buy Stocks for June 11th
by Zacks Equity Research
HOME, SIG, MOD, TGH, and AMN have been added to the Zacks Rank #1 (Strong Buy) List on June 11, 2021.
Here's Why You Should Retain LHC Group (LHCG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of buyouts and a broad array of services.
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
by Zacks Equity Research
Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.
AMN Healthcare (AMN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why You Should Add Veeva Systems (VEEV) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
HealthEquity (HQY) Q1 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
HealthEquity (HQY) delivers solid growth in HSAs along with recording robust Interchange revenues in the first quarter of fiscal 2022.
3 Reasons Growth Investors Will Love AMN Healthcare (AMN)
by Zacks Equity Research
AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.
Here's Why AMN Healthcare Services (AMN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does AMN Healthcare Services (AMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
LHC Group (LHCG) Forays Into Oregon With New Acquisition
by Zacks Equity Research
LHC Group (LHCG) acquires Home 'n Hospice to expand its existing footprint in Idaho.
AMN Healthcare (AMN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.
PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.
Earnings Estimates Rising for AMN Healthcare (AMN): Will It Gain?
by Zacks Equity Research
AMN Healthcare (AMN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
AMN Healthcare (AMN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AMN Healthcare (AMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMN Healthcare (AMN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from segmental strength in the first quarter.
AMN Healthcare (AMN) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AMN Healthcare (AMN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.